Compass Therapeutics (NASDAQ:CMPX) Receives "Buy" Rating from D. Boral Capital

Compass Therapeutics (NASDAQ:CMPX - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at D. Boral Capital in a research note issued on Monday,Benzinga reports. They presently have a $32.00 target price on the stock.

Other research analysts also recently issued reports about the company. HC Wainwright restated a "buy" rating and set a $24.00 target price on shares of Compass Therapeutics in a research note on Monday, April 21st. Guggenheim reiterated a "buy" rating on shares of Compass Therapeutics in a research note on Tuesday, April 22nd. Piper Sandler started coverage on Compass Therapeutics in a report on Wednesday, February 19th. They issued an "overweight" rating and a $12.00 price target for the company. Wedbush reissued an "outperform" rating and set a $8.00 target price on shares of Compass Therapeutics in a research note on Tuesday, April 1st. Finally, Leerink Partners raised shares of Compass Therapeutics from a "market perform" rating to an "outperform" rating and boosted their price target for the stock from $4.00 to $6.00 in a report on Wednesday, April 2nd. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Compass Therapeutics has a consensus rating of "Buy" and a consensus price target of $13.38.

Compass Therapeutics Price Performance

Shares of NASDAQ:CMPX traded down $0.08 during trading hours on Monday, hitting $1.87. The company's stock had a trading volume of 149,617 shares, compared to its average volume of 874,781. The firm's fifty day moving average price is $2.23 and its 200 day moving average price is $2.10. Compass Therapeutics has a 52 week low of $0.77 and a 52 week high of $4.08. The company has a market capitalization of $257.90 million, a price-to-earnings ratio of -5.04 and a beta of 1.40.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). On average, equities research analysts predict that Compass Therapeutics will post -0.36 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Carl L. Gordon sold 3,571,428 shares of Compass Therapeutics stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total transaction of $5,678,570.52. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Jonathan Anderman purchased 20,000 shares of Compass Therapeutics stock in a transaction that occurred on Monday, April 7th. The stock was acquired at an average price of $1.54 per share, with a total value of $30,800.00. Following the transaction, the insider now owns 21,000 shares in the company, valued at $32,340. The trade was a 2,000.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 28.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC lifted its holdings in Compass Therapeutics by 195.4% in the 3rd quarter. Barclays PLC now owns 170,245 shares of the company's stock valued at $314,000 after purchasing an additional 112,614 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Compass Therapeutics by 0.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company's stock valued at $4,251,000 after acquiring an additional 19,095 shares during the period. SG Americas Securities LLC boosted its position in Compass Therapeutics by 921.6% during the 4th quarter. SG Americas Securities LLC now owns 395,017 shares of the company's stock worth $573,000 after purchasing an additional 356,352 shares during the period. Catalina Capital Group LLC purchased a new position in Compass Therapeutics in the fourth quarter valued at about $71,000. Finally, Bleakley Financial Group LLC boosted its position in shares of Compass Therapeutics by 250.7% in the fourth quarter. Bleakley Financial Group LLC now owns 39,993 shares of the company's stock worth $58,000 after buying an additional 28,589 shares during the period. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.